SHENZHEN, China, March 31 /PRNewswire-Asia-FirstCall/ -- Tongjitang
Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a
leading specialty pharmaceutical company focusing on the development,
manufacturing, marketing and selling of modernized traditional Chinese
medicine in China, today announced its financial results for the fourth
quarter of 2009 and for the full year ended December 31, 2009.
Net revenue in the fourth quarter of 2009 increased 31.5% to RMB 151.5 million ($22.2 million) from RMB 115.2 million in the fourth quarter of 2008. Xianling Gubao ("XLGB") sales were RMB 92.0 million ($13.5 million) in the fourth quarter of 2009, compared to RMB 86.7 million in the fourth quarter of 2008. Net revenue from Moisturizing & Anti-itching Capsules and Zaoren Anshen Capsules reached RMB 18.8 million ($2.8 million), an increase of 41.4% from RMB 13.3 million in the prior year period. Net revenue from the Company's other products increased 167.8% to RMB 40.7 million ($6.0 million) from RMB 15.2 million in the fourth quarter of 2008. Revenue contribution from Anhui Jingfang Pharmaceutical Co., Ltd. ("Jingfang"), which was acquired at the end of the first quarter of 2009, was RMB14.0 million ($2.1 million), compared to RMB17.6 million in the third quarter of 2009.
Gross profit increased 20.0% to RMB 84.6 million ($12.4 million) in the fourth quarter of 2009 from RMB 70.5 million in the fourth quarter of 2008. Gross margin was 55.9% in the fourth quarter of 2009, compared to 61.2% in the same period of 2008. Tongjitang's decreased gross margin reflects higher revenue contribution from lower-margin products. The price of barrenwort, used in the production of XLGB, remained stable in the fourth quarter of 2009.
Operating income in the fourth quarter of 2009 was RMB 0.3 million ($0.1 million), compared to an operating loss of RMB 86.2 million in the fourth quarter of 2008. Operating loss in the fourth quarter of 2008 included significant asset impairments to goodwill and intangible assets related to the Guizhou LLF and Qinghai Pulante acquisitions.
Net income attributable to the Company was RMB 4.1 million ($0.6 million), which yielded earnings per ADS of RMB 0.15 ($0.02) and earnings per share2 of RMB 0.04 ($0.01).
Non-GAAP adjusted EBITDA in the fourth quarter of 2009 was RMB 11.4 million ($1.7 million), compared to net loss of Non-GAAP adjusted EBITDA of RMB 75.5 million in the fourth quarter of 2008. Non-GAAP adjusted EBITDA per share was RMB 0.11 ($0.02) in the fourth quarter of 2009, compared to net loss of Non-GAAP adjusted EBITDA per share of RMB 0.56 in the fourth quarter of 2008. For the fourth quarter of 2009, the number of shares used in the computation of GAAP and non-GAAP adjusted EBITDA per share was 106.2 million. Please refer to the Company's GAAP to non-GAAP reconciliation table provided below for additional details.
Financial Results for the Year Ended December 31, 2009
For the year ended December 31, 2009, revenues increased 6.5% to RMB 480.3 million ($70.4 million), from RMB 451.0 million for the full year 2008. During this same time period, gross profit decreased by 1.6% to RMB 279.1 million ($40.9 million) from RMB 283.7 million. Gross margin for the full year 2009 was 58.1%, compared to 62.9% in the year before. Operating loss improved to RMB 10.9 million ($1.6 million) from RMB 77.7 million in the full year 2008. Net loss attributable to the Company was RMB 3.8 million ($0.6 million), or RMB 0.03 ($0. 01) per share, compared to net loss of RMB 52.3 million, or RMB 0.39 per share, in the year before. Net loss per ADS was RMB 0.12 ($0.02) in the year 2009, compared to net loss per ADS of RMB 1.55 in the year 2008. The weighted average number of shares outstanding for the year 2009 was 122.9 million.
Balance Sheet
As of December 31, 2009, the Company had cash and cash equivalents of RMB 237.6 million ($34.8 million). This compares to RMB 310.6 million as of September 30, 2009, and RMB 516.1 million as of December 31, 2008.
Business Updates
On February 2, 2010, the Company announced that it set up a joint venture with a third party to acquire 100% of state-owned Guiyang Liquor Factory for RMB120.6 million in cash. Tongjitang owns 95% of the joint venture and has already completed the acquisition.
On December 23, 2009, the Company held its annual meeting of shareholders for the fiscal year ended December 31, 2009 at its executive office in Shenzhen. At the meeting, Tongjitang's Chairman of the Board of Directors and Chief Executive Officer gave an update on company affairs, and management and stakeholders discussed their views of Tongitang's progress and prospects.
On November 19, 2009, the Company announced the repurchase of 4.8 million ordinary shares, or 4% of the Company's issued and outstanding shares, in privately negotiated transactions.
On October 13, 2009, the Company announced the repurchase of 19.3 million ordinary shares, or 15% of the Company's issued and outstanding shares, in privately negotiated transactions.
On June 22, 2009, the Company announced that effective June 16, 2009, it changed its independent auditor from Deloitte Touche Tohmatsu ("Deloitte") to Ernst & Young Hua Ming.
On April 2, 2009, the Company announced the acquisition of Anhui Jingfang Pharmaceutical Co. Ltd. for RMB 60.0 million in cash. Jingfang began to contribute to Tongjitang's revenue stream upon the closing of the transaction.
About Non-GAAP Financial Measures
To supplement the Company's unaudited condensed consolidated financial information presented in accordance with the United States Generally Accepted Accounting Principles ("GAAP"), the Company also provides non-GAAP financial measures, non-GAAP adjusted EBITDA and non-GAAP adjusted EBITDA per share, all of which exclude depreciation and amortization, interest (income) expense, provision for income taxes and share-based compensation expenses recorded under FASB Accounting Standards Codification ("ASC") Subtopic 718 - 10 Compensation - Stock Compensation: Overall (Pre-codification: SFAS No. 123(R), Share-Based Payment.) The Company's management believes the non-GAAP financial measures facilitate better understanding of operating results from quarter to quarter and allows the management team to better plan and forecast future periods, as the non-GAAP financial measures provide additional information to the investors. The non-GAAP information is not in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for the GAAP results. A limitation of using these non-GAAP financial measures is that these non-GAAP measures exclude share- based compensation expenses that have been and will continue to be significant recurring expenses in our business for the foreseeable future. Reconciliations of the Company's non-GAAP financial data to the most comparable GAAP data are included at the end of this press release.
Conference Call
Tongjitang's management team will hold a conference call on March 31 at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:
About Tongjitang Chinese Medicines Company
Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.
Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit http://www.tongjitang.com for more information.
Safe Harbor Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from those described in the forward-looking statements in this press release. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's heavy dependence on the success of Xianling Gubao; the Company's ability to market Xianling Gubao to hospitals and to retail pharmacies; the retail prices of its principal products' being subject to price control by the government authorities in China; the inclusion of the Company's products in national and provincial medical catalogs of the National Medical Insurance Program in China; the Company's ability to obtain approval from the State Food and Drug Administration in China to convert a provisional national production standard of the Company's principal products to a national final production standard; the Company's ability to continue having the exclusive production rights for its products; the Company's ability to further improve its barrenwort extraction efficiency; the presence of certain side effects in the Company's current products and the Company's ability to identify side effects associated with its current or future products prior to their marketing and sale; the Company's ability to obtain manufacturing or marketing approval for its future products; the Company's dependence on a limited number of distributors for a significant portion of its net revenues; the Company's exposure to the risk of product liability claims and its limited insurance coverage; the Company's ability to manage the expansion of its operations and its future research and development projects successfully; the Company's ability to protect its intellectual property rights and defend infringement or misappropriation claims by third parties; intense competition in the pharmaceutical market in China; the supply of quality medicinal raw materials; the Company's U.S. tax status as a passive foreign investment company ("PFIC") for the taxable year ended December 31, 2008 and the significant risk that the Company will be a PFIC for the current taxable year ended December 31, 2009; uncertainties with respect to the legal system in China, including uncertainty with respect to potential regulatory changes in China's healthcare industry; if disruptions in the financial markets and other macro-economic challenges currently affecting the economy of the United States and other parts of the world continue or even worsen, it may adversely impact the economy and consumer confidence in China; the Company's ability to expand its business through organic growth and strategic acquisitions and investments; and the Company's ability to integrate its acquisitions, including the recently-acquired state-owned Guiyang Liquor Factory. Further information regarding these and other risks is and will be included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of the date of this press release, and the Company undertakes no duty to update such information, except as required under applicable law.
Advertisement
Financial Results for the Quarter Ended December 31, 2009
-- Net revenue increased 31.5% to RMB 151.5 million ($22.2 million)(1),
from RMB 115.2 million in the prior year period.
-- Operating income was RMB 0.3 million ($0.1 million), compared to an
operating loss of RMB 86.2 million in the prior year period.
-- Net income attributable to the Company was RMB 4.1 million
($0.6 million), which yielded earnings per ADS of RMB 0.15 ($0.02) and
earnings per share(2) of RMB 0.04 ($0.01).
-- Non-GAAP adjusted EBITDA per share was RMB 0.11 ($0.02), compared to
net loss of Non-GAAP adjusted EBITDA per share of RMB 0.56 in the
fourth quarter of 2008.
Xiaochun Wang, Chief Executive Officer and Chairman of Tongjitang, stated,
"We are very pleased with our fourth quarter performance, which was a
significant revenue improvement from the fourth quarter of last year. While
our margin performance does reflect a mix shift to lower margin products, we
are operating in a more stable macro environment. Uncertainty in the market
has been greatly reduced by the release and implementation of healthcare
reform, from which we expect to continue to benefit in the long term. The
destocking issues from previous quarters have largely abated, and our sales
have grown as a result. Going forward we will continue to focus on expanding
our sales networks into community hospitals, and we expect these efforts to
result in increased selling and marketing expenses in the near future."Advertisement
Net revenue in the fourth quarter of 2009 increased 31.5% to RMB 151.5 million ($22.2 million) from RMB 115.2 million in the fourth quarter of 2008. Xianling Gubao ("XLGB") sales were RMB 92.0 million ($13.5 million) in the fourth quarter of 2009, compared to RMB 86.7 million in the fourth quarter of 2008. Net revenue from Moisturizing & Anti-itching Capsules and Zaoren Anshen Capsules reached RMB 18.8 million ($2.8 million), an increase of 41.4% from RMB 13.3 million in the prior year period. Net revenue from the Company's other products increased 167.8% to RMB 40.7 million ($6.0 million) from RMB 15.2 million in the fourth quarter of 2008. Revenue contribution from Anhui Jingfang Pharmaceutical Co., Ltd. ("Jingfang"), which was acquired at the end of the first quarter of 2009, was RMB14.0 million ($2.1 million), compared to RMB17.6 million in the third quarter of 2009.
Gross profit increased 20.0% to RMB 84.6 million ($12.4 million) in the fourth quarter of 2009 from RMB 70.5 million in the fourth quarter of 2008. Gross margin was 55.9% in the fourth quarter of 2009, compared to 61.2% in the same period of 2008. Tongjitang's decreased gross margin reflects higher revenue contribution from lower-margin products. The price of barrenwort, used in the production of XLGB, remained stable in the fourth quarter of 2009.
Operating income in the fourth quarter of 2009 was RMB 0.3 million ($0.1 million), compared to an operating loss of RMB 86.2 million in the fourth quarter of 2008. Operating loss in the fourth quarter of 2008 included significant asset impairments to goodwill and intangible assets related to the Guizhou LLF and Qinghai Pulante acquisitions.
Net income attributable to the Company was RMB 4.1 million ($0.6 million), which yielded earnings per ADS of RMB 0.15 ($0.02) and earnings per share2 of RMB 0.04 ($0.01).
Non-GAAP adjusted EBITDA in the fourth quarter of 2009 was RMB 11.4 million ($1.7 million), compared to net loss of Non-GAAP adjusted EBITDA of RMB 75.5 million in the fourth quarter of 2008. Non-GAAP adjusted EBITDA per share was RMB 0.11 ($0.02) in the fourth quarter of 2009, compared to net loss of Non-GAAP adjusted EBITDA per share of RMB 0.56 in the fourth quarter of 2008. For the fourth quarter of 2009, the number of shares used in the computation of GAAP and non-GAAP adjusted EBITDA per share was 106.2 million. Please refer to the Company's GAAP to non-GAAP reconciliation table provided below for additional details.
Financial Results for the Year Ended December 31, 2009
For the year ended December 31, 2009, revenues increased 6.5% to RMB 480.3 million ($70.4 million), from RMB 451.0 million for the full year 2008. During this same time period, gross profit decreased by 1.6% to RMB 279.1 million ($40.9 million) from RMB 283.7 million. Gross margin for the full year 2009 was 58.1%, compared to 62.9% in the year before. Operating loss improved to RMB 10.9 million ($1.6 million) from RMB 77.7 million in the full year 2008. Net loss attributable to the Company was RMB 3.8 million ($0.6 million), or RMB 0.03 ($0. 01) per share, compared to net loss of RMB 52.3 million, or RMB 0.39 per share, in the year before. Net loss per ADS was RMB 0.12 ($0.02) in the year 2009, compared to net loss per ADS of RMB 1.55 in the year 2008. The weighted average number of shares outstanding for the year 2009 was 122.9 million.
Balance Sheet
As of December 31, 2009, the Company had cash and cash equivalents of RMB 237.6 million ($34.8 million). This compares to RMB 310.6 million as of September 30, 2009, and RMB 516.1 million as of December 31, 2008.
Business Updates
On February 2, 2010, the Company announced that it set up a joint venture with a third party to acquire 100% of state-owned Guiyang Liquor Factory for RMB120.6 million in cash. Tongjitang owns 95% of the joint venture and has already completed the acquisition.
On December 23, 2009, the Company held its annual meeting of shareholders for the fiscal year ended December 31, 2009 at its executive office in Shenzhen. At the meeting, Tongjitang's Chairman of the Board of Directors and Chief Executive Officer gave an update on company affairs, and management and stakeholders discussed their views of Tongitang's progress and prospects.
On November 19, 2009, the Company announced the repurchase of 4.8 million ordinary shares, or 4% of the Company's issued and outstanding shares, in privately negotiated transactions.
On October 13, 2009, the Company announced the repurchase of 19.3 million ordinary shares, or 15% of the Company's issued and outstanding shares, in privately negotiated transactions.
On June 22, 2009, the Company announced that effective June 16, 2009, it changed its independent auditor from Deloitte Touche Tohmatsu ("Deloitte") to Ernst & Young Hua Ming.
On April 2, 2009, the Company announced the acquisition of Anhui Jingfang Pharmaceutical Co. Ltd. for RMB 60.0 million in cash. Jingfang began to contribute to Tongjitang's revenue stream upon the closing of the transaction.
About Non-GAAP Financial Measures
To supplement the Company's unaudited condensed consolidated financial information presented in accordance with the United States Generally Accepted Accounting Principles ("GAAP"), the Company also provides non-GAAP financial measures, non-GAAP adjusted EBITDA and non-GAAP adjusted EBITDA per share, all of which exclude depreciation and amortization, interest (income) expense, provision for income taxes and share-based compensation expenses recorded under FASB Accounting Standards Codification ("ASC") Subtopic 718 - 10 Compensation - Stock Compensation: Overall (Pre-codification: SFAS No. 123(R), Share-Based Payment.) The Company's management believes the non-GAAP financial measures facilitate better understanding of operating results from quarter to quarter and allows the management team to better plan and forecast future periods, as the non-GAAP financial measures provide additional information to the investors. The non-GAAP information is not in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for the GAAP results. A limitation of using these non-GAAP financial measures is that these non-GAAP measures exclude share- based compensation expenses that have been and will continue to be significant recurring expenses in our business for the foreseeable future. Reconciliations of the Company's non-GAAP financial data to the most comparable GAAP data are included at the end of this press release.
Conference Call
Tongjitang's management team will hold a conference call on March 31 at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Beijing/Hong Kong time) following the announcement. Listeners may access the call by dialing the following numbers:
United States toll free: 1-888-228-5279
Hong Kong toll free: 800-903-658
Northern China toll free: 10-800-7141504
Southern China toll free: 10-800-1401379
International: 1-913-312-1429
Listeners may access the replay through April 7, 2010, by dialing the
following numbers:
United States toll free: 1-888-203-1112
International: 1-719-457-0820
Password: 1164592
An audio webcast of the call will also be available through the Company's
website at http://www.tongjitang.com .About Tongjitang Chinese Medicines Company
Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.
Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit http://www.tongjitang.com for more information.
Safe Harbor Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from those described in the forward-looking statements in this press release. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's heavy dependence on the success of Xianling Gubao; the Company's ability to market Xianling Gubao to hospitals and to retail pharmacies; the retail prices of its principal products' being subject to price control by the government authorities in China; the inclusion of the Company's products in national and provincial medical catalogs of the National Medical Insurance Program in China; the Company's ability to obtain approval from the State Food and Drug Administration in China to convert a provisional national production standard of the Company's principal products to a national final production standard; the Company's ability to continue having the exclusive production rights for its products; the Company's ability to further improve its barrenwort extraction efficiency; the presence of certain side effects in the Company's current products and the Company's ability to identify side effects associated with its current or future products prior to their marketing and sale; the Company's ability to obtain manufacturing or marketing approval for its future products; the Company's dependence on a limited number of distributors for a significant portion of its net revenues; the Company's exposure to the risk of product liability claims and its limited insurance coverage; the Company's ability to manage the expansion of its operations and its future research and development projects successfully; the Company's ability to protect its intellectual property rights and defend infringement or misappropriation claims by third parties; intense competition in the pharmaceutical market in China; the supply of quality medicinal raw materials; the Company's U.S. tax status as a passive foreign investment company ("PFIC") for the taxable year ended December 31, 2008 and the significant risk that the Company will be a PFIC for the current taxable year ended December 31, 2009; uncertainties with respect to the legal system in China, including uncertainty with respect to potential regulatory changes in China's healthcare industry; if disruptions in the financial markets and other macro-economic challenges currently affecting the economy of the United States and other parts of the world continue or even worsen, it may adversely impact the economy and consumer confidence in China; the Company's ability to expand its business through organic growth and strategic acquisitions and investments; and the Company's ability to integrate its acquisitions, including the recently-acquired state-owned Guiyang Liquor Factory. Further information regarding these and other risks is and will be included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of the date of this press release, and the Company undertakes no duty to update such information, except as required under applicable law.
(1) This announcement contains translations of certain Renminbi amounts
into US dollars at specified rates solely for the convenience of
readers. Unless otherwise noted, all translations from Renminbi to US
dollars as of and for the quarter ended December 31, 2009 were made at
the noon buying rate on December 31, 2009 in the City of New York for
cable transfers in Renminbi per US dollar as certified for customs
purposes by the Federal Reserves Bank of New York, which was RMB6.8259
to USD1.00. Tongjitang makes no representation that the Renminbi or US
dollar amounts referred to in this release could have been or could be
converted into US dollars or Renminbi, as the case may be, at any
particular rate or at all.
(2) All references to "shares" are to our ordinary shares. Each of our
American Depositary Shares, which are traded on the New York Stock
Exchange, represents four ordinary shares.
For further information, please contact:
ICR, Inc.
Ashley M. Ammon or Christine Duan
Tel: +1-203-682-8200 (Investor Relations)
Tongjitang Chinese Medicines Company
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
Fourth Quarter Ended
December 31
2008 2009 2009
RMB RMB US$
(Note)
Net revenues 115,204 151,486 22,193
Cost of revenues 44,736 66,878 9,798
Gross profit 70,468 84,608 12,395
Advertising expenses (18,069) (10,526) (1,542)
Other selling and marketing expenses (22,256) (41,100) (6,021)
General and administrative expenses (20,050) (21,991) (3,222)
Research and development expenses (2,705) (5,880) (861)
Impairment loss on intangible assets (72,910) (4,500) (659)
Impairment loss on goodwill (28,062) -- --
Government grant (related to
research and development) 1,428 200 29
Gain (loss) on disposal of property,
plant and equipment and land
use rights 3,970 (817) (120)
Gain on disposal of a subsidiary 1,312 -- --
Other operating income 710 351 51
Income (loss) from operations (86,164) 345 50
Other income (expenses):
Interest income 3,369 566 83
Interest expense (3,335) (2,129) (312)
Government grants 710 2,009 294
Investment (loss) / gain (175) 309 45
Tax refund on reinvestment of
profits 16,064 -- --
Other income / (expenses), net (14,549) 473 69
Income (loss) before income taxes
and non-controlling interest (84,080) 1,573 229
(Provision for income taxes)
tax benefit 4,826 2,535 371
Net income (loss) (79,254) 4,108 600
Less: Net income (loss) attributable
to the non-controlling interests (10) -- --
Net income (loss) attributable to
controlling interests (79,264) 4,108 600
Earnings per share
Ordinary shares
Basic (0.59) 0.04 0.01
Diluted (0.59) 0.04 0.01
Shares used in computation of
earnings per share
Ordinary shares
Basic 134,929,939 106,153,483 106,153,483
Diluted 134,929,939 106,153,483 106,153,483
Tongjitang Chinese Medicines Company
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
Year Ended
December 31
2008 2009 2009
RMB RMB US$
(Note)
Net revenues 451,032 480,339 70,370
Cost of revenues 167,345 201,205 29,477
Gross profit 283,687 279,134 40,893
Advertising expenses (80,180) (32,384) (4,744)
Other selling and marketing expenses (80,031) (151,755) (22,232)
General and administrative expenses (91,325) (86,501) (12,672)
Research and development expenses (17,368) (16,057) (2,352)
Impairment loss on intangible assets (72,910) (4,500) (659)
Impairment loss on goodwill (28,062) -- --
Government grant (related to
research and development) 1,428 232 34
Gain (loss) on disposal of property,
plant and equipment and land
use rights 3,970 (817) (120)
Gain on disposal of a subsidiary 1,312 -- --
Other operating income 1,801 1,700 249
Income (loss) from operations (77,678) (10,948) (1,603)
Other income (expenses):
Interest income 17,114 4,047 593
Interest expense (16,599) (8,553) (1,253)
Government grants 6,752 5,554 814
Investment (loss) / gain (1,830) 829 121
Tax refund on reinvestment of
profits 16,064 -- --
Other income / (expenses), net 4,171 6,963 1,020
Income (loss) before income taxes
and non-controlling interest (52,006) (2,108) (308)
(Provision for income taxes)
tax benefit (502) (1,617) (237)
Net income (loss) (52,508) (3,725) (545)
Less: Net income (loss)
attributable to the non-controlling
interests 208 (66) (10)
Net income (loss) attributable to
controlling interests (52,300) (3,791) (555)
Earnings per share
Ordinary shares
Basic (0.39) (0.03) (0.01)
Diluted (0.39) (0.03) (0.01)
Shares used in computation of
earnings per share
Ordinary shares
Basic 134,758,695 122,940,745 122,940,745
Diluted 134,758,695 122,940,745 122,940,745
(Note)
The condensed consolidated financial statements of Tongjitang Chinese
Medicines Company are stated in Renminbi ("RMB"). The translation of RMB
amounts as of and for the year ended December 31, 2009 into United States
dollar ("US$") is included solely for the convenience of readers and has
been translated at the rate of RMB6.8259 to US$1.00, which is based on the
noon buying rate in The City of New York for cable transfers of Renminbi
as certified for customs purposes by the Federal Reserve Bank of New York
at December 31, 2009. Such translations should not be construed as
representations that RMB amounts could be converted into US$ at that rate
or any other rate.
Tongjitang Chinese Medicines Company
Condensed Consolidated Balance Sheets
(In thousands, except share data)
Dec. 31 Sept. 30 Dec. 31 Dec. 31
2008 2009 2009 2009
RMB RMB RMB US$
(Note 2) (Note 1)
ASSETS
Current assets:
Cash and cash equivalents 516,087 310,649 237,578 34,805
Short-term bank deposit 50,000 55,000 50,000 7,325
Notes receivable 55,987 41,757 70,248 10,291
Accounts receivable, net of
allowance for doubtful
accounts 214,543 233,966 232,038 33,994
Amounts due from related
parties 8,500 -- -- --
Amounts due from former
shareholders of a
subsidiary 689 -- -- --
Inventories 97,553 134,645 139,100 20,378
Trading securities 792 1,255 1,447 212
Prepaid advertising expenses 1,692 4,359 1,204 176
Receivable on sales of
property, plant and
equipment 12,600 18,810 9,320 1,365
Other prepaid expenses and
current assets, net of
allowance for doubtful
accounts 21,548 33,161 16,139 2,364
Deferred tax assets -- 1,533 6,771 992
Total current assets 979,991 835,135 763,845 111,902
Property, plant and equipment,
net 152,249 174,118 172,097 25,212
Land use rights, net 28,902 42,468 42,515 6,228
Deposit for acquisition of a
subsidiary -- -- 120,599 17,668
Deposits for acquisition of
property, plant and
equipment and intangible
assets 188,103 163,170 162,440 23,798
Acquired intangible assets,
net 24,736 33,242 27,592 4,042
Goodwill -- 4,475 2,345 344
Receivable on sales of
property, plant and
equipment 6,210 -- 9,170 1,343
Long-term other assets 1,800 441 1,000 147
Deferred tax assets 1,107 1,165 3,603 528
Total assets 1,383,098 1,254,214 1,305,206 191,212
LIABILITIES AND SHAREHOLDERS'
EQUITY
Current liabilities:
Short-term borrowings 85,100 103,100 101,100 14,811
Accounts payable 14,663 23,854 38,288 5,610
Amounts due to related
parties 1,332 900 900 132
Amounts due to former
shareholders of a
subsidiary 7,385 6,186 5,186 760
Accrued expenses and other
current liabilities 81,130 92,856 156,247 22,890
Income taxes payable 926 2,894 4,026 590
Total current
liabilities 190,536 229,790 305,747 44,793
Long-term bank loans 50,000 50,000 50,000 7,325
Deferred tax liabilities 7,272 9,073 11,868 1,739
Total liabilities 247,808 288,863 367,615 53,857
Total shareholders' equity
attributable to the Company 1,134,815 965,351 937,591 137,358
Non-controlling interests
(Note 2) 475 -- -- --
Total equity 1,135,290 965,351 937,591 137,358
Total liabilities
and equity 1,383,098 1,254,214 1,305,206 191,215
(Note 1)
The condensed consolidated financial statements of Tongjitang Chinese
Medicines Company are stated in Renminbi ("RMB"). The translation of RMB
amounts as of and for the year ended December 31, 2009 into United States
dollar ("US$") is included solely for the convenience of readers and has
been translated at the rate of RMB6.8259 to US$1.00, which is based on the
noon buying rate in The City of New York for cable transfers of Renminbi
as certified for customs purposes by the Federal Reserve Bank of New York
at December 31, 2009. Such translations should not be construed as
representations that RMB amounts could be converted into US$ at that rate
or any other rate.
(Note 2)
Effective from January 1, 2009, the Company adopted FASB ASC Topic 810
"Noncontrolling Interest" ("ASC 810") (Pre-codification: SFAS 160,
Noncontrolling Interests in Consolidated Financial Statements), which
amends ARB 51 to establish accounting and reporting standards for
noncontrolling interests in a subsidiary. FASB ASC 810 further clarifies
that a noncontrolling interest in a subsidiary is an ownership interest in
the consolidated entity that should be reported in the financial
statements. Accordingly, the Company has included the noncontrolling
subsidiary minority interests in the current year financial statements and
adjusted the previous year periods for comparative presentation.
Additionally, net loss attributable to non-controlling interests was shown
separately from net loss in the accompanying condensed consolidated
statement of operations. Reclassifications -- Certain prior period
balances have been reclassified to conform with current period
presentation related to the adoption of ASC 810 "Noncontrolling Interest."
Tongjitang Chinese Medicines Company
Reconciliation of GAAP to Non-GAAP
(In thousands, except share and per share data)
Fourth Quarter Ended December 31
2008 2009 2009
RMB RMB US$
(Note 1)
GAAP net income (79,264) 4,108 600
Share-based compensation expenses
(Note 2) 1,996 1,599 234
Depreciation and amortisation 6,602 6,622 970
Interest (income) expense, ne (34) 1,563 229
Provision for income taxes (4,826) (2,535) (371)
Non-GAAP adjusted EBIDTA (75,526) 11,357 1,662
GAAP earnings per share
Ordinary shares
Basic (0.59) 0.04 0.01
Diluted (0.59) 0.04 0.01
Non-GAAP adjusted EBIDTA per share
Ordinary shares
Basic (0.56) 0.11 0.02
Diluted (0.56) 0.11 0.02
Shares used in computation of
GAAP/Non-GAAP adjusted EBIDTA per
share
Ordinary shares
Basic 134,929,939 106,153,483 106,153,483
Diluted 134,929,939 106,153,483 106,153,483
Tongjitang Chinese Medicines Company
Reconciliation of GAAP to Non-GAAP
(In thousands, except share and per share data)
Year Ended December 31
2008 2009 2009
RMB RMB US$
(Note 1)
GAAP net income (52,300) (3,791) (555)
Share-based compensation expenses
(Note 2) 20,446 5,799 850
Depreciation and amortisation 25,819 22,970 3,365
Interest (income) expense, net (515) 4,506 660
Provision for income taxes 502 1,617 237
Non-GAAP adjusted EBIDTA (6,048) 31,101 4,557
GAAP earnings per share
Ordinary shares
Basic (0.39) (0.03) (0.01)
Diluted (0.39) (0.03) (0.01)
Non-GAAP adjusted EBIDTA per share
Ordinary shares
-Basic (0.04) 0.25 0.04
-Diluted (0.04) 0.25 0.04
Shares used in computation of GAAP
/ Non-GAAP adjusted EBIDTA per
share
Ordinary shares
-Basic 134,758,695 122,940,745 122,940,745
-Diluted 134,758,695 122,940,745 122,940,745
(Note 1)
The condensed consolidated financial statements and the related amounts of
Tongjitang Chinese Medicines Company are stated in Renminbi ("RMB"). The
translation of RMB amounts as of and for the year ended December 31, 2009
into United States dollar ("US$") is included solely for the convenience
of readers and has been translated at the rate of RMB6.8259 to US$1.00,
which is based on the noon buying rate in The City of New York for cable
transfers of Renminbi as certified for customs purposes by the Federal
Reserve Bank of New York at December 31, 2009. Such translations should
not be construed as representations that RMB amounts could be converted
into US$ at that rate or any other rate.
(Note 2)
Share-based compensation expenses recorded in accordance to ASC subtopic
718-10 ("ASC 718-10"), Compensation-Stock Compensation: Overall (Pre-
Codification: SFAS No. 123(R), Share-Based Payment) are as follows:
Forth Quarter Ended September 30
2008 2009 2009
RMB RMB US$
(Note 1)
General and administrative expenses 1,996 1,599 234
Year Ended December 31
2008 2009 2009
RMB RMB US$
(Note 1)
General and administrative expenses 20,446 5,799 850
SOURCE Tongjitang Chinese Medicines Company